During the last session, Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s traded shares were 45.52 million, with the beta value of the company hitting 1.44. At the end of the trading day, the stock’s price was $0.85, reflecting an intraday loss of -2.84% or -$0.02. The 52-week high for the DNA share is $2.55, that puts it down -200.0 from that peak though still a striking 4.71% gain since the share price plummeted to a 52-week low of $0.81. The company’s market capitalization is $1.72B, and the average trade volume was 24.85 million shares over the past three months.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Ginkgo Bioworks Holdings Inc (DNA) registered a -2.84% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.84% in intraday trading to $0.85, hitting a weekly high. The stock’s 5-day price performance is -2.96%, and it has moved by -22.40% in 30 days. Based on these gigs, the overall price performance for the year is -33.40%.
Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts
Statistics show that Ginkgo Bioworks Holdings Inc has outperformed its competitors in share price, compared to the industry in which it operates. Ginkgo Bioworks Holdings Inc (DNA) shares have gone down -43.23% during the last six months, with a year-to-date growth rate more than the industry average at 17.95% against 12.90. In the rating firms’ projections, revenue will decrease -11.20% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 46.04M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 53.28M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 80.7M and 80.57M respectively. In this case, analysts expect current quarter sales to shrink by -43.00% and then drop by -33.90% in the coming quarter.
While earnings are projected to return 30.43% in 2024, the next five years will return 19.50% per annum.
DNA Dividends
Ginkgo Bioworks Holdings Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
